[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometriosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometriosis":642},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,164,0,25,[9,46,62,106,129,151,187,219,239,269,291,313,344,366,385,415,438,456,478,502,522,540,576,596,616],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054009",false,"NCT06785129","Endometriosis and Migraine","Mechanisms Underlying Endometriosis and Migraine Comorbidity","EMC","Inclusion Criteria:\n\n1. Patients with diagnosed endometriosis, migraine, or both endometriosis and migraine\n2. Healthy control subjects with no history of chronic pain\n3. Age 12-45\n4. Assigned female sex at birth\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Presence of prolactinoma\n3. Presence of psychiatric, neurological, endocrinological and\u002For developmental conditions and taking medications for these conditions\n4. Current use of dopamine agonist or SSRI medications\n5. For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health",true,"FEMALE","12 Years","45 Years",{"count":22,"type":23},120,"ESTIMATED","OBSERVATIONAL","This study aims to determine differences in experimental pain and sex hormone levels between patients with migraine, patients with endometriosis, patients with migraine and endometriosis, and healthy controls. Participants will complete surveys, experimental pain paradigms and collection of samples for hormone analyses.",[27,28],"Migraine","Endometriosis",[27,30,31,32],"endometriosis","hormones","pain","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2025-02-12",{"date":41,"type":23},"2030-01-01",{"name":43,"class":44},"Washington University School of Medicine","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":45},"100053243","NCT06101303","Endometriosis Pain","The Mechanisms Underlying Endometriosis Pain","Inclusion criteria:\n\n* Patients with pelvic pain with and without endometriosis scheduled for an operative laparoscopic surgery for endometriosis diagnosis and\u002For treatment\n* Age 12-45\n* Females\n\nExclusion criteria:\n\n* Pregnancy\n* Planned hysterectomy or oophorectomy\n* Co-occurring vaginismus and\u002For vulvodynia\n* For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health",{"count":22,"type":23},"Aim 1. To determine the factors contributing to pain in patients with chronic pelvic pain with and without endometriosis Aim 2. To determine the changes following endometriosis lesion removal surgery in pain and sex hormone levels.\n\nAim 3. To identify factors predicting clinical pain reduction after lesion removal surgery.\n\nAdditional exploratory aims might compare subgroups of patients such as patients with vs. without endometriosis, with vs. without additional chronic pain syndromes, and with vs. without hormonal treatment. In addition, the role of lesion-specific immune signatures and psychological factors on pain will be explored.\n\nPatients with pelvic pain potentially due to endometriosis will complete questionnaires including social, health, behavioral, and psychological questionnaires. Patients will also complete a 2.5 hours study visit of psychophysical assessments of thermal and pressure stimuli. In addition, blood, urine, and saliva samples will be collected for hormonal, immune, and genetic analyses. Additional samples might be collected and stored for future analyses. For some participants, these procedures will be completed several times, including before the surgery as well as 3 months, 6 months and 1 year after surgery. After the surgery, surveys assessing pain and other symptoms will be sent every week on the first month and then monthly for 1 year. In addition, during the surgery, biopsies will be collected and analyzed to determine hormonal, immune and genetic factors.\n\nFor adolescents, a parent\u002Flegal guardian will be asked to assist in completing some of the health-related surveys (i.e., physical developmental survey, health survey, migraine history survey).",[55,28],"Pelvic Pain",{"date":36,"type":37},{"date":58,"type":37},"2023-09-29",{"date":60,"type":23},"2029-09-01",{"name":43,"class":44},{"id":63,"slug":4,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100645235","NCT07679074","CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life","A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions","CREST","Inclusion Criteria:\n\n* Self-identified female, aged 18-65 years at the time of enrollment\n* Basic English literacy\n* Able and willing to provide informed consent electronically\n* Residing in the United States\n* Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)\n* Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships\n* Currently in full-time employment with medical benefits as part of compensation package\n* Access to a smartphone with internet access compatible with the Samphire mobile application\n* Able to safely operate the study device in the home environment\n* Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or actively planning pregnancy during the study period\n* History of epilepsy or seizure disorder\n* Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation\n* Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use\n* Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use\n* Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening\n* Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening\n* Inability to provide informed consent or safely use the device in the home environment\n* Current participation in another interventional neurotechnology or drug study","18 Years","65 Years",{"count":72,"type":23},50,"This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program\n\n* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.",[75,76,77,28,78,79,55],"Premenstrual Syndrome","Premenstrual Dysphoric Disorder","Dysmenorrhea","Perimenopause","Menopause",[81,82,83,84,85,86,87,88,89,90,91,92,93,94,95],"tDCS","neuromodulation","hormonal health","menstrual symptoms","perimenopause","menopause","PMDD","PMS","work productivity","brain fog","mood","cognitive function","digital health","decentralized clinical trial","guided care","2026-06-25",{"date":98,"type":37},"2026-07-01",{"date":100,"type":37},"2026-06-01",{"date":102,"type":23},"2027-03-01",{"name":104,"class":105},"Samphire Group, Inc.","INDUSTRY",{"id":107,"slug":4,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":24,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100611461","NCT07240883","ENDO1000 - A UK-wide Endometriosis Research Project","INCLUSION CRITERIA\n\n1. Aged 16 or over\n2. Participants who confirm that they have received a clinical diagnosis of endometriosis (based on MRI, ultrasound or laparoscopy) within the last 10 years\n3. Living within the UK\n4. Willing and able to consent to installing and using the mobile ENDO1000 app on their smartphone or use our web-based equivalent.\n\nEXCLUSION CRITERIA\n\n1. Pregnant\n2. Known severe coagulation disorder\n3. Known active Hepatitis B\u002FC and\u002For HIV (due to Royal Mail restrictions on biospecimen postage)","16 Years",{"count":113,"type":23},1000,"2 Years","Approximately 1.5 million people in the UK, and 200 million globally live with endometriosis, and it is estimated to affect 1 in 10 women of reproductive age. Endometriosis is a chronic pain condition where the lining of the uterus (endometrium) grows in areas outside the uterus. This can cause patients a range of symptoms including severe pain, fatigue, irregular periods, infertility and gastrointestinal symptoms.\n\nThere is a clear unmet need for early diagnosis and more effective pain management for people who suffer from endometriosis. Endometriosis is a heterogeneous disease in terms of symptoms, trajectory, and indicated therapeutic course, which highlights the need to develop personalised\u002Ftargeted approaches for effective longitudinal management which are acceptable and accessible to patients and their health care team.\n\nThe goal of this study is to accelerate discovery and advance data-driven research into endometriosis diagnosis and treatment by collecting large, multimodal, longitudinal data.\n\nTo achieve this goal, the investigators plan to deliver a longitudinal cohort study. Approximately 3000 UK individuals with endometriosis will be invited over a 24-month period to self-report symptoms that include, pain, menstrual cycle, painkiller use, sleep, exercise, diet and bowel habits via a bespoke ENDO1000 mobile app. A cohort of 1000 women will be asked to complete more in-depth questionnaires asking about endometriosis history, quality of life and treatments. This cohort of women will be asked to take self-collected biological samples (blood, urine, saliva, vaginal swab and faeces). The investigators will look at, for example, inflammatory markers, examine the microbiome and may look at DNA, with permission to see if there are any markers that can help with diagnosis or treatment of endometriosis. At the same time participants will be asked to wear a smartwatch which will monitor, for example, temperature, ambient light, sleep patterns and movement. All this will help the investigators to build a picture over time of the participant's endometriosis symptoms, treatments and what may cause symptoms to flare which in turn could lead to more patient led treatments.",[28],[28,55,118,119],"Longitudinal","Mobile app","2026-06-23",{"date":122,"type":37},"2026-06-24",{"date":124,"type":37},"2025-12-05",{"date":126,"type":23},"2030-12-31",{"name":128,"class":44},"University of Edinburgh",{"id":130,"slug":4,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":20,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":45},"100579142","NCT06820450","Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis","STERONLINE: Steroidome and Exposome of Endometriosis Single-center Case-control Study","STERONLINE","Inclusion Criteria:\n\n* Women aged 18 to 45\n* Free, informed and written consent from the patient to participate in the study\n* Good understanding of the French language\n* Patient affiliated to or benefiting from a social security or similar scheme\n\nSpecific inclusion criteria for each group:\n\nGroup 1. Controls.\n\n* Women with no laparoscopically confirmed signs suggestive of deep endometriosis.\n* No clinico-biological criteria in favour of a diagnosis of endometriotic disease, nor any radiological signs (ultrasound or MRI) suggestive of endometriosis.\n\nGroup 2. Cases of deep endometriosis.\n\n* Newly diagnosed women (less than 12 months).\n* Severe, deep endometriotic pathology with surgical indication (clinical examination, imaging tests, pre-operative findings).\n\nExclusion Criteria:\n\n* Intercurrent diagnosis of pregnancy.\n* Presence of other hormone-dependent pathologies (e.g. breast cancer, PCOS).\n* Acute infection.",{"count":137,"type":23},135,"Endometriosis is a systemic, steroid-dependent, inflammatory disease characterized by the growth of endometrial-like tissue outside the uterus, affecting approximately 10 % of women of childbearing age. The etiology and pathophysiology of endometriosis is not completely understood to support effective treatment and prevention strategies. Despite the steroid dependency, little is known concerning the underlying metabolism of estrogen and other tightly related steroids. Moreover, shortening the long diagnostic delays is a major priority in endometriosis research.",[28],[141,142,143],"Steroidome","exposome","LC-HRMS",{"date":122,"type":37},{"date":146,"type":37},"2025-07-01",{"date":148,"type":23},"2027-07-01",{"name":150,"class":44},"Nantes University Hospital",{"id":152,"slug":4,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":172,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":185,"locationsCount":45},"100644230","NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates",{"count":158,"type":23},36,"INTERVENTIONAL",[161],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[164,165,166,167,168,28,169,170,171],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Chronic Pelvic Pain","Menorrhagia","Endometritis","Adnexal Diseases",[173,174,175,176,177,178],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":122,"type":37},{"date":98,"type":23},{"date":184,"type":23},"2026-12-01",{"name":186,"class":44},"Christiana Care Health Services",{"id":188,"slug":4,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":159,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":45},"100641783","NCT07652593","Interaction Between Decidual Cells and NK Cells in Endometriosis","Interaction Between Decidual Cells and Natural Killer Cells in Endometriosis: A Prospective Pilot Case-Control Study","PAINLESS","Inclusion Criteria:\n\n* Endometriosis Group\n* Female participant aged 18 years or older.\n* Confirmed diagnosis of deep endometriosis by imaging or surgery.\n* Pelvic pain and\u002For severe dysmenorrhea (Visual Analog Scale \\> 4).\n* Premenopausal.\n* No contraceptive or hormonal treatment during the study menstrual cycle.\n* Affiliated with a health insurance system.\n* Able and willing to provide written informed consent.\n* Control Group\n* Female participant aged 18 years or older.\n* No diagnosis of endometriosis.\n* Premenopausal.\n* No contraceptive or hormonal treatment during the study menstrual cycle.\n* No chronic pelvic pain or severe dysmenorrhea (Visual Analog Scale \\\u003C 4).\n* Affiliated with a health insurance system.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Current infection.\n* Active cancer.\n* Active autoimmune disease.\n* Concomitant hormonal treatment.\n* Pregnancy.\n* Participant under guardianship or legal protection.\n* Participant deprived of liberty.",{"count":72,"type":23},[196],"NA","Endometriosis is a chronic gynecological disease characterized by the presence of endometrial-like tissue outside the uterus and is frequently associated with pelvic pain and infertility. Increasing evidence suggests that immune dysfunction may contribute to the development and persistence of the disease.\n\nThe purpose of this prospective case-control study is to compare immune cell characteristics in women with deep endometriosis and women without endometriosis during the secretory phase of the menstrual cycle. Participants will undergo collection of clinical data, blood samples, endometrial samples, and vaginal microbiota samples. For participants undergoing clinically indicated pelvic surgery, additional biological samples may be collected during the procedure. The study aims to improve understanding of the immune mechanisms involved in endometriosis and to identify potential biomarkers associated with the disease.",[28],[28,200,201,202,203,204,205,206,55,207,208,209],"Deep Endometriosis","Natural Killer Cells","NK Cells","Endometrial Immune Microenvironment","CD39","Immunology","Vaginal Microbiota","Cytokines","Women's Health","Biomarkers","2026-06-11",{"date":212,"type":37},"2026-06-17",{"date":214,"type":23},"2026-06",{"date":216,"type":23},"2027-10",{"name":218,"class":44},"Hopital Foch",{"id":220,"slug":4,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":159,"phases":226,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":45},"100549858","NCT06439524","The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial","Inclusion criteria\n\n* Age ≥ 18 years\n* Planning to undergo an elective laparoscopic or robotic procedure for known or suspected endometriosis\n\nExclusion criteria\n\n-A known contraindication to REL-CT. Contraindications include:\n\n* High risk of arterial, venous thrombotic, or thromboembolic disorder\n* Pregnancy Known osteoporosis\n* Current or history of breast cancer or other hormone-sensitive malignancies\n* Known hepatic impairment or disease\n* Undiagnosed abnormal uterine bleeding\n* Known hypersensitivity to components of Rel-CT\n* The patient did not discontinue hormonal suppression within the required timeline:\n\nTrans-Dermal, Oral Medication, Patch, or Vaginal Ring: day before surgery\n\nIntrauterine Device or Sub-Dermal Implant: removed at surgery\n\nInjectable Medication: at least 12 weeks before surgery\n\n* Primary language other than English\u002FSpanish\n* Interested in pregnancy within the 6 months following the surgical procedure.\n* If pregnancy test performed during pre-surgical work up is positive, the patient will no longer be a candidate for endometriosis surgery and will therefore not be eligible for the study.\n* Patients without histologic evidence of endometriosis following their surgical procedure will be removed from the study prior to receiving the study intervention.\n* Patients who undergo a surgical intervention more invasive than the planned laparoscopic or robotic excisional surgery, such as open abdominal surgical repair, will be removed from the study prior to receiving the study intervention.",{"count":225,"type":23},110,[227],"PHASE3","The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an FDA approved form of medical treatment for endometriosis. It is known to work in treating endometriosis pain. However, investigators do not know whether or not there is a benefit to beginning Rel-CT immediately following surgery. This study will test if patients who take Rel-CT after surgery have better quality of life and less chance the endometriosis comes back, requiring additional surgery.\n\nThe main question it aims to answer is:\n\n\\- Does taking Rel-CT following excisional surgery for endometriosis result in higher Endometriosis Health Profile 30 (EHP-30) scores, indicating a positive impact on overall health-related quality of life and well-being?\n\nParticipants will:\n\n* Be randomly assigned to one of two treatment groups. One treatment group will take study drug Rel-CT after having excisional surgery, and the other treatment group will just have the surgery alone.\n* Be asked to complete questionnaires, called the Endometriosis Health Profile 30 (EHP-30) at 4 timepoints. The first time is before surgery, then at follow-up visits at 1 month, 3 months, and 6 months. The survey has 30 questions that ask about pain, control, powerlessness, emotional well-being, social support, and self-image.\n\nResearchers will compare the two treatment groups (Rel-CT and non Rel-CT) to see if there is a change in EHP-30 scores.",[28],"2026-06-10",{"date":232,"type":37},"2026-06-12",{"date":234,"type":37},"2024-08-15",{"date":236,"type":23},"2028-12-01",{"name":238,"class":44},"Main Line Health",{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":159,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100642530","NCT07645196","Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With Dysmenorrhea","Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With Dysmenorrhea With or Without Endometriosis","Inclusion Criteria:\n\n* female sex\n* aged 18 to 50 years\n* clinical diagnosis of dysmenorrhea (cyclic pelvic pain during menstruation)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Delivery less than 1 year prior to enrollment\n* History of abdominal or pelvic surgery within the past 3 months\n* Diagnosis of fibromyalgia, diabetes, or cancer\n* Ongoing manual therapy treatment of the abdominal or genital area","50 Years",{"count":247,"type":23},80,[196],"Dysmenorrhea affects up to 90% of women of reproductive age and represents a significant public health concern. Beyond prostaglandin-mediated uterine contractions, dysmenorrhea involves central sensitization mechanisms and myofascial components, including abdominal trigger points. Despite growing interest in physiotherapy for chronic pelvic pain, objective data on tissue-level changes induced by manual therapy remain scarce.\n\nThis randomized single-blind sham-controlled trial aims to evaluate the effects of abdominal manual mobilization techniques on (1) tissue stiffness measured by shear wave elastography at the uterine cervix and bilateral abdominal regions, and (2) clinical outcomes including pain intensity and quality of life in women with dysmenorrhea, with or without endometriosis.\n\nParticipants will be randomly assigned to either a treatment group receiving standardized abdominal manual therapy or a sham group receiving superficial manual contact. Assessments will be conducted over three menstrual cycles using shear wave elastography, the Numeric Rating Scale (NRS), and the SF-36 questionnaire.",[77,28],[77,30,252,253,254,255,256,257,258,259],"Shear wave elastography","Manual therapy","Physiotherapy","Abdominal mobilization","Tissue stiffness","Chronic pelvic pain","Central sensitization","Menstrual pain","2026-06-08",{"date":232,"type":37},{"date":263,"type":23},"2026-09",{"date":265,"type":23},"2028-09",{"name":267,"class":44},"Vrije Universiteit Brussel",2,{"id":270,"slug":4,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":276,"targetDuration":278,"studyType":24,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100643762","NCT07635199","Histological Evaluation of Dual-wavelength Diode Laser Ablation of Ovarian Endometrioma","Histological Evaluation of Ovarian Endometrioma Ablation Using a Dual-wavelength Diode Laser (LEONARDO® DUAL 45): a Pilot Study","DUALENDO","Inclusion Criteria:\n\n* Female participants aged 18 years or older\n* Ultrasound diagnosis of at least one unilateral or bilateral ovarian endometrioma measuring ≥3 cm in maximum diameter\n* Scheduled for laparoscopic surgery (cystectomy or adnexectomy)\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Suspected ovarian malignancy based on preoperative clinical or imaging evaluation\n* Presence of concomitant pelvic disease requiring complex surgical management or potentially interfering with histological assessment (e.g., pelvic inflammatory disease)\n* Medical conditions contraindicating laparoscopic surgery\n* Inability or unwillingness to provide written informed consent",{"count":277,"type":23},30,"6 Months","Background: Ovarian endometrioma is the most common manifestation of endometriosis and is associated with chronic pelvic pain, infertility, and reduced ovarian reserve. Surgical treatment options include cystectomy and ablative techniques. Recent evidence suggests that ablative approaches may better preserve ovarian reserve compared with cystectomy while maintaining comparable recurrence and pregnancy rates. However, limited histological data are available regarding the depth of tissue damage induced by ablative techniques and their ability to completely eradicate endometriotic tissue.\n\nObjective: This pilot study aims to histologically evaluate the effects of ex vivo ovarian endometrioma ablation using the LEONARDO® DUAL 45 dual-wavelength diode laser (980 nm and 1470 nm). The study will assess the completeness of endometriotic tissue ablation, the depth of laser-induced necrosis within the endometrioma pseudocapsule, and the extent of thermal injury to the surrounding ovarian tissue.\n\nMethods: Adult women undergoing laparoscopic surgery for unilateral or bilateral ovarian endometriomas ≥3 cm will be prospectively enrolled. Surgical treatment will consist of cystectomy in reproductive-age women and adnexectomy in selected peri- or postmenopausal women according to routine clinical practice. After surgical excision, ex vivo samples of the internal endometrioma wall will undergo laser ablation using two different laser settings. Histological examination will evaluate residual endometrial glands and stroma, depth of necrosis, and thermal damage to adjacent ovarian tissue. Clinical, surgical, and pathological data will also be collected.\n\nStudy Design: Prospective, observational, pilot study involving a medical device. Approximately 30 patients will be enrolled, generating multiple histological specimens for analysis. The study is designed to provide preliminary evidence regarding the histological efficacy and tissue effects of dual-wavelength diode laser ablation of ovarian endometriomas.",[281,28],"Ovarian Endometrioma","2026-06-03",{"date":284,"type":37},"2026-06-09",{"date":286,"type":23},"2026-06-07",{"date":288,"type":23},"2027-12-30",{"name":290,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":292,"slug":4,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":18,"minAge":297,"maxAge":245,"enrollmentInfo":298,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100458136","NCT05245695","Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)","Deep Neural Network Stratification for the Use in Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)","Inclusion Criteria:\n\n* Participant is willing and able to provide written informed consent.\n* Participant is a female aged 14 to 50 years old at time of consent.\n* Participant is scheduled to undergo laparotomy or laparoscopy for symptomology consistent with possible endometriosis\n\nExclusion Criteria:\n\n* Participant is a female in a pre-menarchal state.\n* Participant is pregnant.\n* Participant has an active malignancy.\n* Participant is known to have tested positive for human immunodeficiency virus or hepatitis A, B, or C.\n* Participant has an active pelvic infection or other infections contraindicated for surgery.\n* Participant has participated (±3 months of study enrollment) in a clinical trial where an investigational drug\u002F device\u002F procedure was or is planned to be administered.\n* Participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation.\n* Participant is under 14 years old or over 50 years old","14 Years",{"count":299,"type":23},1200,"The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - \"EndoCheck\" - as an \"aid in diagnosis\" for endometriosis and to show validity as a diagnostic test",[28],[28,209,303],"Deep neural network",{"date":305,"type":37},"2026-06-04",{"date":307,"type":37},"2022-07-12",{"date":309,"type":23},"2026-06-30",{"name":311,"class":105},"Aspira Women's Health",10,{"id":314,"slug":4,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":322,"conditions":323,"keywords":331,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":268},"100517943","NCT06024109","Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy","Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy","BARHYSTER","Inclusion Criteria:\n\n* Females undergoing an elective, laparoscopic total hysterectomy\n* Age ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Open surgery\n* Patients undergone immunosuppressive drug treatment within the prior 6 months\n* Patients with hypersensitivity or allergy to the suture material.\n* Participation in another clinical study\n* Non-compliance of patient",{"count":321,"type":23},132,"The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate.\n\nSecondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.",[324,28,325,326,327,328,329,330],"Abnormal Uterine Bleeding","Uterine Prolapse","Uterine Cancer","Ovarian Cancer","Fallopian Tube Cancer","Cervical Cancer","Endometrial Cancer",[332,333,334,335],"Barbed Suture","Hysterectomy","Laparoscopy","Minimal Invasive",{"date":337,"type":37},"2026-06-02",{"date":339,"type":37},"2024-03-19",{"date":341,"type":23},"2027-08",{"name":343,"class":105},"Aesculap AG",{"id":345,"slug":4,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":45},"100633231","NCT07523997","Imaging of Endometriosis With Total-body PET-CT (PET-Endo)","Novel Non-invasive Imaging of Endometriosis Using Total-body PET-CT Programme (PET-Endo)","PET-Endo","Inclusion Criteria:\n\n* Chronic pelvic pain\n* Clinical\u002Fradiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent\n* Actively trying to conceive, pregnant or breastfeeding\n* Post menopausal (no periods for \\>12 months and not taking hormonal treatments to prevent periods or bilateral oophorectomy performed)\n* Previous hysterectomy\n* Confirmed or suspected pelvic malignancy\n* Contraindication to MRI (ferromagnetic material in the body, metallic device implantation or claustrophobia)\n* Contraindication to buscopan (e.g. glaucoma, unstable cardiac disease, arrythmias, myasthenia, previous hypersensitivity to buscopan)\n* Taking part in a CTIMP or interventional non-CTIMP study\n* Previous severe pelvic inflammatory disease\n* Previous peritonitis","60 Years",{"count":277,"type":23},"Endometriosis is a disease that affects 1 in 10 women and is associated with debilitating pain and infertility. Endometriosis is where cells similar to those lining the womb (the 'endometrium') grow elsewhere in the body, forming 'lesions'. Most commonly the lesions grow on the lining of the pelvic cavity, called 'peritoneal' endometriosis. Lesions can also grow on the ovary, this is called 'ovarian' endometriosis, or form nodules, called 'deep' endometriosis.\n\nAt present the only way to confidently identify endometriosis is through surgery, this exposes patient to the risks of surgery and contributes to the diagnostic delay associated with endometriosis.\n\nPET\u002FCT is a specialist scan that is commonly used to identify cancers which cannot be seen on other types of scans. PET\u002FCT uses a 'tracer', a substance given into a vein which then temporarily accumulates in areas of disease.\n\nThis project will determine if a new specialist scan, total body PET\u002FCT, and novel tracers that were developed for other conditions can be used to identify some of the key pathways in endometriosis: bleeding and scarring. Being able to identify these processes in endometriosis lesions and being able to track how they change over time would improve our understanding of endometriosis. The investigators also want to know if these pathways are different between superficial, deep and ovarian endometriosis, and what the impact is of the hormones related to the menstrual cycle.\n\nIn this study up to 30 people who have suspected endometriosis and are already due to undergo diagnostic surgery will be asked to undergo two total-body PET\u002FCT scans in Edinburgh, one at one visit and one another visit. Participants will also have a PET\u002FMRI scan at visit. Participants will have a different tracer at each visit. The investigators will then compare the scan findings with their subsequent surgical findings.",[28],[28,356,357],"PET-CT","PET-MRI","2026-05-22",{"date":360,"type":37},"2026-05-27",{"date":362,"type":37},"2026-04-08",{"date":364,"type":23},"2027-12-31",{"name":128,"class":44},{"id":367,"slug":4,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":371,"minAge":69,"maxAge":20,"enrollmentInfo":372,"targetDuration":4,"studyType":159,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":45},"100559109","NCT06559852","The Impact of Yoga on Endometriosis-Related Pain","Inclusion Criteria:\n\n1. Reproductive aged women 18-45\n2. Self-reported prior surgery with pathology confirming a diagnosis of endometriosis\n3. No current use of yoga\n4. Baseline moderate pain, score greater than or equal to 5 on VAS scoring\n5. Access to internet with wifi capability for zoom platform and completion of weekly surveys\n6. Access to items required for yoga session participation (2 blankets or towels, firm pillow, stable chair, wall space, comfortable clothing, water)\n7. Ability to commit to duration of 12-week yoga course\n\nExclusion Criteria:\n\n1. Pregnant patients\n2. Established yoga participation or moderate exercise regimen\n3. Physical trauma or disability\n4. Planned surgery or hormonal medication change during study\n5. Non-English speaking patients","ALL",{"count":277,"type":23},[196],"The central hypothesis of the investigators is that the practice of yoga will result in an improvement of endometriosis related pain symptoms for women with endometriosis.",[28],[55],"2026-05-20",{"date":358,"type":37},{"date":380,"type":23},"2026-08-15",{"date":382,"type":23},"2026-09-15",{"name":384,"class":44},"Milton S. Hershey Medical Center",{"id":386,"slug":4,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":159,"phases":395,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":414},"100633178","NCT07523308","Efficacy and Safety of Intra-operative Dual Laparoscopy and Neo-rectoscopy for Bowel Endometriosis: The LUMEN-01 Trial","Efficacy and Safety of Intra-operative Dual Laparoscopy and Neo-rectoscopy (IDLnR) Versus Conventional Laparoscopic Surgery for Bowel Endometriosis: A Multicenter, Open-Label, Randomized Controlled Trial (LUMEN-01)","LUMEN-01","Inclusion Criteria:\n\n* Premenopausal women aged 18 to 55 years.\n* Preoperative pelvic contrast-enhanced MRI and\u002For transrectal endosonography confirmed bowel endometriosis (BE) lesions involving the muscular layer of the intestinal wall, located in the rectum and\u002For sigmoid colon. Postoperative pathological diagnosis serves as the gold standard.\n* Pre-treatment LARS score \\> 20.\n* Eligible for laparoscopic surgery.\n* Voluntarily participated in this study and signed written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Presence of active inflammatory bowel disease, irritable bowel syndrome, or other similar conditions with disease flare-ups within the past 1 year.\n* Acute or severe infectious disease within 4 weeks prior to surgery.\n* History of malignant tumor, or highly suspected gynecological\u002Fgastrointestinal malignancy based on preoperative imaging or tumor marker tests.\n* American Society of Anesthesiologists (ASA) physical status classification ≥ Grade Ⅲ, or severe cardiac, pulmonary, hepatic, renal, or coagulation dysfunction that precludes general anesthesia and elective laparoscopic surgery.\n* Undergoing robot-assisted laparoscopic surgery or open laparotomy.\n* Currently participating in other clinical trials that may affect the outcome assessment of this study.\n* Previous participation in other interventional clinical trials that may affect the outcome assessment of this study.\n* History of colorectal resection and anastomosis or stoma surgery.\n* History of pelvic radiotherapy.","55 Years",{"count":394,"type":23},192,[196],"The goal of this prospective, multicenter, randomized controlled trial is to compare the clinical efficacy and safety of intra-operative dual laparoscopy and neo-rectoscopy (IDLnR) versus conventional laparoscopy (CL) in patients with bowel endometriosis (BE) undergoing surgery. The primary objective is to assess differences in postoperative bowel function improvement at 6 months between the two groups.\n\nThe main questions it aims to answer are:\n\nIs there a significant difference in postoperative bowel function (primary endpoint) at 6 months postoperatively between IDLnR and CL groups? Do the two groups differ in secondary outcomes, including efficacy indicators (LARS score\u002Fcure rate\u002Fimprovement rate, CRADI-8, Wexner score, GIQLI, EHP-30, VAS pain reduction) and safety indicators (30-day severe complications, antibiotic use intensity, hospital stay \\>7 days)? Researchers will randomize BE surgical patients to IDLnR or CL groups, then compare the above primary and secondary endpoints to evaluate IDLnR's clinical value.\n\nParticipants will undergo either IDLnR or CL surgery for BE lesions, and be followed up to assess bowel function, quality of life, pain, and safety outcomes as specified.\n\nThis study will fill evidence gaps for IDLnR in BE surgery, support its standardized application, optimize BE treatment strategies, and aim for complete lesion resection, preserved intestinal function, and improved long-term patient quality of life.",[398,28,399],"Bowel Endometriosis","Intestinal Endometriosis",[398,401,402,403,404],"Intra-operative Dual Laparoscopy and Neo-rectoscopy (IDLnR)","Efficacy","Safety","LARS","2026-05-16",{"date":407,"type":37},"2026-05-19",{"date":409,"type":37},"2026-04-13",{"date":411,"type":23},"2028-05-31",{"name":413,"class":44},"Obstetrics & Gynecology Hospital of Fudan University",3,{"id":416,"slug":4,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":159,"phases":423,"briefSummary":424,"conditions":425,"keywords":426,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":45},"100639455","NCT07603960","Whole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis","An Exploratory Clinical Trial to Determine the Impact of Whole-body Cryotherapy on Endometriosis-associated Pain","CHILL-Endo","Inclusion Criteria:\n\n* Women or assigned female at birth\n* Aged 16 or over\n* Endometriosis identified at laparoscopy or imaging, performed within the last ten years\n* Chronic pelvic pain for more than six months\n* Willing to comply with the treatment\n* Willing to use effective contraception throughout the trial (if needed)\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or actively trying to get pregnant\n* Post-menopausal (no periods for \\>12 months and not taking hormonal treatments to prevent periods, or bilateral oophorectomy performed)\n* Previous hysterectomy with bilateral oophorectomy\n* Raynaud's Disease\n* Current treatment for malignancy\n* Diabetes\n* Known hypothyroidism\n* Pre-existing or current diagnosis of anaemia\n* Cardiovascular disease: severe hypertension (180\u002F100, unstable angina, arrhythmia, recent (\\\u003C6months) myocardial infarction, peripheral artery disease, cardiac pacemaker, recent (\\\u003C6months) stroke or transient ischaemic attack)\n* Acute kidney and urinary tract diseases\n* Cryoglobulinemia\n* Previous venous thromboembolism or peripheral artery occlusive disease\n* Cold urticaria\n* Livedo reticularis\n* Open wounds or ulcers, large-area bacterial and viral skin infections\n* Uncontrolled seizure disorder\n* Known coagulopathy (eg von Willibrand disease, haemophilia)\n* Severe claustrophobia\n* Acute infections and fever\n* Intoxication (alcohol, drugs)\n* Signs or symptoms of cold allergy\n* Severe wasting diseases\n* Known Hepatitis B\u002FC and\u002For HIV (due to Royal Mail restrictions on biospecimen postage)",{"count":277,"type":23},[196],"The aim of this study is to investigate whether whole-body cryotherapy (a brief exposure to very cold temperatures) can help reduce pain and improve quality of life in people living with endometriosis, and whether it may represent a safe, non-pharmacological approach to managing endometriosis-related symptoms.\n\nUp to 30 participants with symptomatic endometriosis (chronic pelvic pain for more than six months) will be recruited over a 12-month period. Participants will attend two study visits at the hospital, approximately four weeks apart. Between these visits, participants will undergo five whole-body cryotherapy sessions, each lasting approximately 3 minutes. During cryotherapy, participants stand in a specialised chamber where the body is briefly exposed to cold, dry air (around -120°C).\n\nDuring the study, will be assessed changes in systemic inflammation and biological markers using blood, saliva, urine, vaginal, and stool samples. Data will be collected using questionnaires evaluating pain and related symptoms, quality of life, sleep, fatigue, intestinal symptoms, and overall wellbeing.\n\nThe active study phase lasts approximately 4-6 weeks. A final follow-up assessment at 15 weeks will be conducted remotely using questionnaires and self-collected samples.",[28],[30,427,428,32,429,430],"cryotherapy","inflammation","chronic pelvic pain","endometriosis-associated pain","2026-05-15",{"date":358,"type":37},{"date":434,"type":37},"2026-04-09",{"date":436,"type":23},"2027-05-31",{"name":128,"class":44},{"id":439,"slug":4,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":159,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":45},"100636680","NCT07568834","Impact of Pelvic Pain Podcast","\"Impact of an Educational Podcast for Patients With Chronic Pelvic Pain\"","Inclusion Criteria:\n\n* Being seen as a new patient or consult visit by provider in the division of minimally invasive gynecology surgery for chronic pelvic pain or endometriosis\n* 18 years of age or older\n* Understand English\n* Has an email address and personal device with capability to listen to an audio podcast\n\nExclusion Criteria:\n\n* Not able to speak English\n* Being seen for acute pelvic pain",{"count":445,"type":23},100,[196],"The purpose of this research study is to study the impact of an educational podcast on pelvic pain. If you decide to take part in this research, you may receive the standard treatment for pelvic pain, or you may receive the standard treatment plus access to an educational podcast series. You will be randomly assigned to receive access to the podcast or to receive standard care. If you are assigned to receive access to the podcast, participating in this research will involve listening to a podcast series. All participants will complete three ten-minute online surveys over the course of 6 months. Reasons you may choose to participate in this research are if you want to learn more about pelvic pain and possible benefits of listening to the podcast, such as improved quality of life, reduced stigma, or increased satisfaction with your medical care.",[168,28],{"date":407,"type":37},{"date":451,"type":37},"2026-05-05",{"date":453,"type":23},"2027-08-01",{"name":455,"class":44},"Vanderbilt University Medical Center",{"id":457,"slug":4,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":20,"enrollmentInfo":462,"targetDuration":4,"studyType":159,"phases":464,"briefSummary":465,"conditions":466,"keywords":469,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":45},"100637189","NCT07592403","Efficacy of Pulsed Electromagnetic Field Therapy on Women With Endometriosis","Efficacy of Pulsed Electromagnetic Field Therapy on Women With Endometriosis, A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Women aged 18 to 45 years\n2. Clinically, radiologically, or laparoscopically diagnosed endometriosis\n3. Chronic pelvic pain persisting for at least 6 months\n4. Stable pharmacological or hormonal treatment for at least 3 months before enrollment\n5. Ability to understand study procedures and provide written informed consent\n\nExclusion Criteria:\n\n1. Pregnancy or planned pregnancy during the study period\n2. History of gynecological or pelvic malignancy\n3. Active pelvic inflammatory disease or acute pelvic infection\n4. Implanted electronic medical devices such as pacemakers or neurostimulators\n5. Previous pelvic surgery within the past 6 months\n6. Participation in another clinical trial during the previous 3 months\n7. Neurological, rheumatological, or severe musculoskeletal disorders affecting assessment procedures\n8. Contraindications to electromagnetic therapy",{"count":463,"type":23},60,[196],"This randomized, sham-controlled, double-blinded clinical trial aims to investigate the effects of pulsed electromagnetic field therapy (PEMF) on pain intensity, quality of life, and pelvic floor morphometric changes assessed by four-dimensional trans perineal ultrasound (4D TPUS) in women diagnosed with endometriosis. Participants will be randomly allocated into either a PEMF therapy group or a sham PEMF control group. Both groups will continue receiving stable standard medical care throughout the study period. Assessments will be conducted at baseline, after completion of the 8-week intervention period, and at 3-month follow-up.",[28,467,468],"Pulsed Electromagnetic Therapy","Trans Perineal Ultrasound",[28,470,471],"Pulsed Electromagnetic Field Therapy","trans perineal ultrasound",{"date":407,"type":37},{"date":405,"type":37},{"date":475,"type":23},"2027-01-30",{"name":477,"class":44},"Beni-Suef University",{"id":479,"slug":4,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":20,"enrollmentInfo":485,"targetDuration":4,"studyType":159,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":45},"100532403","NCT06212349","Therapeutic-educational Physiotherapy on Pain, Physical-functionality and Quality of Life in Women With Endometriosis.","Effect of a Therapeutic-educational Physiotherapy Program on Pain and the Physical-functional Sphere in Women With Endometriosis and Its Impact on Quality of Life","PHYSIO_ENDOM","Inclusion Criteria:\n\n* Diagnosis of endometriosis made by imaging techniques (MRI or ultrasound) or by surgery.\n* A period of 3 months or more since the last surgery if they have undergone surgery.\n* Who are receiving hormone treatment and have their disease under control.\n* Persistent pelvic pain for at least 3 months.\n* With pain and hypertonus in the pelvic musculature, myofascial syndrome, vestibulodynia or pudendal neuropathy.\n* Consent to participate in the study\n* Capable of carrying out the follow-up of the study until the final visit.\n* Who have audiovisual resources and the internet at their disposal.\n\nExclusion Criteria:\n\n* Women in the menopausal phase\n* Women undergoing fertility treatment or planning to undergo fertility treatment in the next 3 months.\n* Pregnant women.\n* Women undergoing physiotherapy treatment or who have undergone physiotherapy treatment in the last 3 months.\n* Having suffered a fracture in the last 3 months in the lower limb that limits their functional capacity.\n* Cognitive illness that prevents correct comprehension of the exercises.\n* Musculoskeletal pathology or neuropathy in acute phase.\n* Having suffered or suffering from a neoplastic disease.\n* Untreated endometriosis\n* Acquired genital abnormalities of the pelvis or pelvic floor.\n* Women in a situation of litigation or economic compensation, or pending the granting of a degree of disability.\n* Severe mental illness (schizophrenia, borderline personality disorder, etc.)",{"count":486,"type":23},62,[196],"This is a randomized clinical trial that will be carried out in women with endometriosis divided into two groups: the experimental group (EG) that will receive therapeutic-educational physiotherapy, which will combine therapeutic exercise with a pain education program, and the control group (CG) who will receive the pain education program.\n\nThe participants will be evaluated at three moments: before starting the study (T1), after the 8-week treatment program (T2) and after another 8 weeks of follow-up in which they will be encouraged to continue with the treatment (T3). The initial assessment will include a medical and physiotherapy history, and at T1, T2 and T3 the following will be assessed: pain, abdominopelvic mobility, muscle status, functionality, sexual function, quality of life, stress and biomarkers of chronic inflammation.",[28,490,208],"Chronic Pain",[30,490,492,493,494],"Physical Therapy","Health education","Women",{"date":407,"type":37},{"date":497,"type":37},"2024-09-09",{"date":499,"type":23},"2027-12-22",{"name":501,"class":44},"University of Valencia",{"id":503,"slug":4,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":45},"100638710","NCT07591441","Endometriosis Self-Management Strategies","Endometriosis Self-Management Strategies: Exploring Empowerment and Abandonment Through Lived Experiences","EUmetriosis","Inclusion Criteria:\n\n* living in a European country\n* 16 years or older\n* having been diagnosed with endometriosis or very likely to have endometriosis based on a previous assessment, even if not having received a definitive surgical diagnosis\n* fluent in a language spoken by the research team\n\nExclusion Criteria:\n\n* not meeting one of the inclusion criteria",{"count":510,"type":23},150,"The goal of this observational study is to document the lived experiences of self-managing endometriosis in people living with endometriosis who live in Europe. The main question it aims to answer is: \\[How\\] do support structures across personal, community, healthcare, and institutional levels influence individuals' experiences of empowerment and abandonment in self-managing endometriosis?\n\nParticipants will describe the everyday actions they take to live with endometriosis, through diary studies, interviews, and focus groups.",[28,513],"Self-management","2026-05-12",{"date":431,"type":37},{"date":517,"type":37},"2026-01-19",{"date":519,"type":23},"2029-12-31",{"name":521,"class":44},"Wageningen University and Research",{"id":523,"slug":4,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":20,"enrollmentInfo":529,"targetDuration":4,"studyType":159,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":45},"100640907","NCT07590895","Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms","Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms: a Randomized Controlled Trial","FODMAPendo","Inclusion Criteria:\n\n* Age between 18 and 45 years\n* BMI between 18.5 and 24.9,\n* Surgical, clinical or instrumental diagnosis of endometriosis\n* Presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, on estro-progestin or progestin treatment or in the absence of hormonal treatment\n\nExclusion Criteria:\n\n* Associated conditions that may cause pelvic pain independent of the presence of endometriosis (e.g., pelvic varices and salpingitis outcomes)\n* chronic inflammatory bowel disease (Crohn's disease or ulcerative rectocolitis).\n* patients with obstructive uropathy, subocclusive intestinal stenosis\n* complex adnexal masses or typical endometriomas greater than 5 cm in diameter.\n* women who are obese (BMI ≥ 30) or underweight (BMI \\\u003C 18)\n* women on vegetarian-vegan dietary regimens,\n* women with metabolic diseases that require specific dietary indications such as in the case of diabetes and celiac disease.",{"count":510,"type":23},[196],"The main objective of the study is to assess whether a dietary regimen based on the principles of the FODMAP diet, compared with the current treatment programme which does not include specific dietary recommendations, can improve pain symptoms in patients with symptomatic endometriosis and intestinal symptoms (i.e. bloating, nausea, constipation, diarrhoea and vomiting) attributable to irritable bowel syndrome, compared with a control group",[28],{"date":431,"type":37},{"date":535,"type":37},"2024-03-01",{"date":537,"type":23},"2026-12-15",{"name":539,"class":44},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":159,"phases":549,"briefSummary":550,"conditions":551,"keywords":560,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":45},"100629184","NCT07471373","Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut\u002FGenital Microbiome Signatures in Women With Endometriosis","PestiEndoMicro","Inclusion Criteria:\n\n* The \"case\" group will include:\n* All women aged 18 to 43, with confirmed endometriosis and endometriosis grade 3 or 4 as defined by the 1985 revised version of the American Society of Reproductive Medicine.\n* The \"control\" group will include:\n* All women aged between 18 and 43, whose infertility problem is proven male infertility and who do not have endometriosis identified by biological, genetic and clinical tests.\n* The following criteria will apply to both groups:\n* All women who have not received antibiotic treatment in the three months preceding inclusion and who are not participating in any pharmacological study.\n* All women who are covered under the national social security health insurance scheme.\n* All women who have signed a written informed consent form, thereby confirming their participation in the study after a period of free and informed reflection.\n\nExclusion Criteria:\n\n* All women aged 44 and over.\n* Women who are overweight, obese or anorexic.\n* Women taking antibiotics 3 months prior to inclusion, or participating in a drug study.\n* All women under anti-GnRH treatment, pregnant or suffering from a chronic inflammatory disease such as Crohn's disease, polycystic ovary syndrome, etc.\n* All women whose endometriosis has not been formally confirmed by the tests offered by the Reproductive Medicine and Biology Department, CECOS de Picardie, CHU Amiens-Picardie.\n* All patients under guardianship, curators or safeguard of justice.\n* All patients who have not signed the written consent confirming their participation in the study, after a period of free and informed reflection.\n* Any patient who withdraws her consent for participation in the study.","43 Years",{"count":548,"type":23},160,[196],"This project PestiEndoMicro aims to provide an innovative approach, studying endometriosis under the genital and gut microbiota scope. To realize this project, the investigators are planning to dose cfDNA to assess the oxidative stress caused by endometriosis and study its epigenetics. At the same time, the investigators will take a pragmatic approach by assessing pesticide exposure in these patients and estimate the correlation between gut or genital dysbiosis and chemical agent exposure. Also, the investigators will take the initiative to use classic culture, qPCR techniques, and NGS to establish signatures in vaginal, endometrial and gut microbiota in patients with endometriosis. With these approaches, the goal is to gain more knowledge about endometriosis and optimize early diagnosis by establishing a signature in the genital and gut microbiota, but also by dosing the cfDNA. By doing so the investigators could open new opportunities to develop new therapeutic strategies for endometriosis.",[28,552,553,554,555,206,556,557,558,559],"Infertility","Female Fertility","Cell Free DNA","Genital Microbiota","Endometrial Microbiota","Pesticides","Gut Microbiota","Epigenetics",[28,552,561,562,563,564,565,566,567,568],"Female fertility","cell free DNA","genital microbiota","vaginal microbiota","endometrial microbiota","pesticides","gut microbiota","epigenetics",{"date":431,"type":37},{"date":571,"type":37},"2026-02-27",{"date":573,"type":23},"2028-05",{"name":575,"class":44},"Centre Hospitalier Universitaire, Amiens",{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":17,"sex":18,"minAge":297,"maxAge":582,"enrollmentInfo":583,"targetDuration":278,"studyType":24,"phases":4,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":593,"locationsCount":595},"100635514","NCT07553676","Multicenter Study for Diagnostic Validation of a Laboratory Test for the Diagnosis of Endometriosis","Multicenter Studie Zur Diagnostischen Validierung Eines Labortests Zur Endometriose-Diagnose","Inclusion criteria:\n\n* Women aged 14 to 49\n* Menstruating\n* Endometriosis group\n\n  * Histologically confirmed endometriosis\n  * Imaging-verified endometriosis\n* Laparoscopy-negative group:\n\n  \\- Laparoscopy with no evidence of endometriosis\n* Imaging-negative group:\n\n  * Healthy women (no symptoms of endometriosis)\n  * Imaging shows no evidence of endometriosis\n\nExclusion criteria:\n\n* Amenorrhea\n* Pregnancy\n* Oncological diseases\n* Use of GnRH agonists or antagonists","49 Years",{"count":584,"type":23},200,"Endometriosis affects at least 1 in 10 women worldwide and is associated with a diagnostic delay of 5-10 years. Currently, definitive diagnosis requires invasive laparoscopy, which is costly and burdensome for patients.\n\nThis multicenter diagnostic validation study investigates a non-invasive laboratory test for the diagnosis of endometriosis based on the analysis of biomarkers from menstrual blood samples.\n\nStudy Objective:\n\nThe primary objective is to evaluate the diagnostic accuracy of a laboratory protocol for biomarker analysis from menstrual blood samples. Performance metrics including Area Under the Curve (AUC), sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) will be assessed by comparing women with confirmed endometriosis to confirmed controls.\n\nStudy Design:\n\nThis is a prospective multicenter diagnostic study. Menstrual blood samples are self-collected by participants.\n\nParticipants:\n\nA total of 200 menstruating women aged 14-49 years will be enrolled across study sites. Participants are allocated to one of two cohorts.\n\nStudy Sites:\n\nThe study is conducted at multiple gynecological centers in Austria and Germany, with planned expansion to additional sites.\n\nSponsor: Diamens FlexCo, Linz, Austria\n\nExpected Study Duration: 3 years",[28],"2026-05-06",{"date":589,"type":37},"2026-05-11",{"date":587,"type":37},{"date":592,"type":23},"2029-12-01",{"name":594,"class":105},"Diamens FlexCo",8,{"id":597,"slug":4,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":20,"enrollmentInfo":602,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":604,"conditions":605,"keywords":606,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":268},"100640191","NCT07578480","MEN-ENDO: Menstrual Stem Cells in Endometriosis","Study of the Role of Menstrual Blood-derived Stem Cells and the Immune Environment in Endometriosis","Inclusion Criteria:\n\n* 18-45 years.\n* Endometriosis group: Women with clinical and\u002For ecographical diagnostic of endometriosis.\n* Control group: Women with the endometriosis diagnosis.\n\nExclusion Criteria:\n\n* \\\u003C18 years or \\>45 years.\n* Pregnancy or lactation.\n* Diagnosis of prior chronic pelvic inflammatory or autoimmune disease.\n* History of active gynecological cancer.\n* Positive for human immunodeficiency virus (HIV) or human papillomavirus (HPV).\n* Hormonal therapy use in the previous 3 months.\n* Use of immunosuppressants or corticosteroids in the previous 3 months.\n* Systemic antibiotics use in the previous 3 months.\n* Insufficient menstrual flow to allow the MenSCs isolation.",{"count":603,"type":23},40,"Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.\n\nEndometriosis involves complex changes in the body's cells and immune response. For this reason, the goal of this observational study is to characterize the functional, molecular, and immunological alterations in menstrual blood-derived stem cells (MenSCs) and differentiated decidual stromal cells in women with endometriosis; to validate these findings in endometrial tissue and endometriomas; and to establish their correlation with clinical parameters, with the aim of identifying key pathogenic mechanisms and potential therapeutic targets.\n\nThe main questions it aims to answer are:\n\n* Are there functional and molecular changes in MenSCs from patients with endometriosis compared to healthy volunteers?\n* Are there any variations in the immune properties of MenSCs throughout the menstrual bleeding period in patients with endometriosis compared to healthy volunteers?\n* Are these changes also present in endometrial tissue and endometrioma samples?\n* Can these changes be correlated with clinical parameters in patients with endometriosis?\n* Can MenSCs serve as a potential therapeutic target for endometriosis?\n\nSome participants will be asked to provide menstrual blood on a single day, while others will provide samples during the first five days of menstruation. Additionally, all participants will answer questionnaires about their diet, physical activity, stress, and pain levels. Therefore, the study does not involve the evaluation of a specific intervention on the participants.\n\nThe results will enable the identification of key altered mechanisms and potential therapeutic targets, thereby contributing to the development of more effective strategies for the diagnosis and treatment of the disease.",[28],[607,608],"Menstrual blood-derived stem cells","Menstrual blood",{"date":589,"type":37},{"date":611,"type":23},"2026-04",{"date":613,"type":23},"2028-04",{"name":615,"class":44},"Francisco Algaba Chueca",{"id":617,"slug":4,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":18,"minAge":69,"maxAge":20,"enrollmentInfo":623,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":4},"100636787","NCT07570225","Innovative Non-Invasive Diagnostics and Personalized Treatment Strategies for Endometriosis Through Advanced Multi-Omics and Ultrasound Integration","Innovativa Icke-invasiva Diagnostiska Och Personliga Behandlingsstrategier för Endometrios Genom Avancerad Multi-omik Och Ultraljudsintegration","ENDO-NOVA","Inclusion Criteria:\n\n* Women aged 18-45\n* Understands and speaks the Swedish language\n* Suspected or confirmed endometriosis\n\nExclusion Criteria:\n\n* Do not have a uterus",{"count":624,"type":23},365,"Endometriosis is a prevalent gynecological condition affecting approximately 10% of women of reproductive age worldwide. It presents with nonspecific but often severe symptoms, including chronic pelvic pain (in 70% of cases) and infertility (in up to 40% of cases), imposing significant physical, psychological, economic, and societal burdens. Despite its widespread occurrence, the exact etiology and pathogenesis of endometriosis remain unclear, and no definitive cure exists. Early diagnosis and management are crucial for improving patient outcomes; however, major diagnostic delays persist. Current imaging techniques such as transvaginal ultrasound (TVUS) examination and magnetic resonance imaging, along with biochemical markers lack sufficient specificity. Consequently, confirmation of diagnosis still requires surgical procedures under general anesthesia, i.e.\n\nlaparoscopy (\"key-hole surgery\") and tissue biopsy. This delay exacerbates the disease burden and healthcare costs, underscoring the urgent need for non-invasive, precise diagnostic strategies. This project proposes a multi-modal approach integrating advanced ultrasound imaging with novel biomarkers identified via comprehensive multi-omics analyses, including proteomics, transcriptomics, and immune profiling, of patient-derived endometrial organoids. It aims to understand the underlying mechanisms of reduced endometrial receptivity of embryos in patients with endometriosis. Additionally, we will explore personalized treatment strategies by utilizing patient-specific organoids for drug screening and evaluation of treatment response.\n\nThis project aims to develop a non-invasive diagnostic strategy by integrating:\n\n1. AI-enhanced TVUS for improved lesion detection.\n2. Multi-omics biomarker discovery through proteomics, transcriptomics, and immune profiling.\n3. Underpinning the mechanisms of reduced endometrial receptivity in endometriosis using an in vitro model of embryo-endometrium interaction.\n4. Endometrial organoid models to enable precision medicine-based drug testing. The development of a reliable noninvasive or minimally invasive diagnostic test-or a combination of tests-could revolutionize the diagnostic pathway by reducing delays, avoiding the need for surgery, and facilitating disease monitoring and treatment evaluation.",[28,627],"Infertility, Female",[629,630,631,632],"Transvaginal ultrasound","AI","Multi-omics","Organoid","2026-04-29",{"date":587,"type":37},{"date":636,"type":23},"2026-04-20",{"date":638,"type":23},"2029-04-20",{"name":640,"class":641},"Region Stockholm","OTHER_GOV",""]